Biotech News
Related news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
RLAYRelay Therapeutics2026-07-30 20:05 EST
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
IMCRImmunocore Holdings plc2026-07-30 11:00 EST
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
RVMDRevolution Medicines2026-07-29 20:05 EST
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
KYMRKymera2026-07-28 20:01 EST
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST
BioCryst to Report Second Quarter 2026 Financial Results on August 5
GERNGeron2026-07-22 11:00 EST
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
BNTXBioNTech2026-07-21 10:45 EST
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
Exelixis
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...
Recent company news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
EXELExelixis2026-05-30 14:00 EST
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
EXELExelixis2026-05-27 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Stock data
- Close
- 52.20 USD
- Market cap
- 12.2B USD
- Exchange
- NASDAQ
- Sector
- Small Molecule Drugs
- Location
- United States